FDA Approves Methylphenidate Transdermal Patch for Treatment of ADHD

Methylphenidate Transdermal Patch (Daytrana, Shire/Noven) approved for treatment of children with ADHD
Methylphenidate transdermal is delivered via a transdermal patch applied to dry skin on either hip, thus allowing the medication to be directly absorbed into the patient’s bloodstream for 9 hours.

The starting dose of seligiline transdermal is a 10 mg/9 hour patch, but dosing can be titrated to a 30 mg/9 hour patch over 4 weeks if response is not maximized. The once-daily patch should be applied in the early morning; placement should alternate each day (ie, right hip one day, left the next). For further information, go to: www.daytrana.com